2020/06/02
CIC bioGUNE and Atlas Molecular Pharma discuss new therapeutic strategies against autoimmune diseases and cancer
A CIC bioGUNE project, in which the Basque biotech company Atlas Molecular Pharma is also participating, has been selected by the European Commission within its ITN program. The commission has chosen 147 projects from among the more than 1500 applications submitted.
The Glytunes Project is coordinated by University of Naples Federico II and consists of 7 research institutions and 4 biotechnology companies in Europe.
At CIC bioGUNE, Glytunes is chaired by June Ereño Orbea, Ikerbasque research fellow in the Chemical Glycobiology group, while Oscar Millet, CEO of Atlas Molecular Pharma, is responsible for research at this company.
Glytunes seeks to tackle new therapeutic strategies against autoimmune diseases and cancer. Specifically, the objective is to understand, on a molecular scale, how aberrant interactions between immunomodulators known as Siglecs and their ligands, sialic acid-containing sugars, contribute to the etiology of immune diseases. The ultimate goal is to develop glycobiotechnological therapeutic approaches for the development of molecules that modulate these interactions.
The 4-year project has been funded with more than 3.7 million euros, of which more than half a million will be employed for research within CIC bioGUNE and Atlas Molecular Pharma.
See a large version of the first picture